Ribo Life Science executive Dr. Gan Liming lifts personal stake by 6,800 H shares, cumulative purchase reaches 20,000 shares

Bulletin Express07-10

Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that executive director, co-chief executive officer and global R&D president Dr. Gan Liming bought 6,800 H shares of the company on the open market using personal funds.

The latest transaction raises Dr. Gan’s total open-market purchases to 20,000 H shares as of 10 July 2026. According to the announcement, Dr. Gan expressed confidence in the Group’s long-term development prospects and indicated that, subject to regulatory compliance, further purchases remain possible.

The board advised shareholders and potential investors to exercise caution when dealing in the company’s securities.

The announcement was signed by Chairman Liang Zicai and dated 10 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138010880?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138010880","market":"us","top_or_hot":-1,"title":"Ribo Life Science executive Dr. Gan Liming lifts personal stake by 6,800 H shares, cumulative purchase reaches 20,000 shares","media":"Bulletin Express","content":"<p>Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that executive director, co-chief executive officer and global R&D president Dr. Gan Liming bought 6,800 H shares of the company on the open market using personal funds.</p>\n<p>The latest transaction raises Dr. Gan’s total open-market purchases to 20,000 H shares as of 10 July 2026. According to the announcement, Dr. Gan expressed confidence in the Group’s long-term development prospects and indicated that, subject to regulatory compliance, further purchases remain possible.</p>\n<p>The board advised shareholders and potential investors to exercise caution when dealing in the company’s securities.</p>\n<p>The announcement was signed by Chairman Liang Zicai and dated 10 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ribo Life Science executive Dr. Gan Liming lifts personal stake by 6,800 H shares, cumulative purchase reaches 20,000 shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRibo Life Science executive Dr. Gan Liming lifts personal stake by 6,800 H shares, cumulative purchase reaches 20,000 shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-10 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that executive director, co-chief executive officer and global R&D president Dr. Gan Liming bought 6,800 H shares of the company on the open market using personal funds.</p>\n<p>The latest transaction raises Dr. Gan’s total open-market purchases to 20,000 H shares as of 10 July 2026. According to the announcement, Dr. Gan expressed confidence in the Group’s long-term development prospects and indicated that, subject to regulatory compliance, further purchases remain possible.</p>\n<p>The board advised shareholders and potential investors to exercise caution when dealing in the company’s securities.</p>\n<p>The announcement was signed by Chairman Liang Zicai and dated 10 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"","article_id":"1138010880","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138010880","pubTimestamp":1783678987,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that executive director, co-chief executive officer and global R&D president Dr. Gan Liming bought 6,800 H shares of the company on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B"},"translate_title":"日博生命科学高管甘黎明博士增持6800股H股，累计增持2万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that executive director, co-chief executive officer and global R&D president Dr. Gan Liming bought 6,800 H shares of the company on the open market using personal funds.\nThe latest transaction raises Dr. Gan’s total open-market purchases to 20,000 H shares as of 10 July 2026. According to the announcement, Dr. Gan expressed confidence in the Group’s long-term development prospects and indicated that, subject to regulatory compliance, further purchases remain possible.\nThe board advised shareholders and potential investors to exercise caution when dealing in the company’s securities.\nThe announcement was signed by Chairman Liang Zicai and dated 10 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138010880","isCrawlerRequest":true}